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Abstract
Background: The polycomb complex protein BMI-1 (BMI-1) is a putative oncogene reported to be overexpressed
in multiple myeloma (MM). Silencing of BMI-1 was shown to impair the growth and survival of MM cells. However,
therapeutic agents specifically targeting BMI-1 were not available so far. Here, we investigated PTC-209, a novel
small molecule inhibitor of BMI-1, for its activity in MM.
Methods: BMI-1 expression was analysed in human MM cell lines and primary MM cells by using publically
available gene expression profiling (GEP) data. The anti-MM activity of PTC-209 was investigated by viability testing,
cell cycle analysis, annexin V and 7-AAD staining, quantification of cleaved poly(ADP-ribose) polymerase (PARP), JC-1
as well as colony formation assays. Deregulation of central myeloma growth and survival genes was studied by
quantitative PCR and flow cytometry, respectively. In addition, the impact of PTC-209 on in vitro osteoclast,
osteoblast and tube formation was analysed.
Results: We confirmed overexpression of BMI-1 in MM patients by using publically available GEP datasets. Of note,
BMI-1 expression was further increased at relapse which translated into significantly shorter overall survival in
relapsed/refractory patients treated with bortezomib or dexamethasone.
Treatment with PTC-209 significantly decreased viable cell numbers in human MM cell lines, induced a G1 cell cycle
arrest, promoted apoptosis and demonstrated synergistic activity with pomalidomide and carfilzomib. The anti-MM
activity of PTC-209 was accompanied by a significant decrease of cyclin D1 (CCND1) and v-myc avian
myelocytomatosis viral oncogene homolog (MYC) expression as well as upregulation of cyclin-dependent kinase
inhibitor 1A (CDKN1A) and cyclin-dependent kinase inhibitor 1B (CDKN1B). We also observed upregulation of NOXA
(up to 3.6 ± 1.2-fold induction, P = 0.009) and subsequent downregulation of myeloid cell leukemia 1 (MCL-1)
protein levels, which likely mediates the apoptotic effects of PTC-209. Importantly, the anti-MM activity was upheld
in the presence of stromal support or myeloma growth factors insulin-like growth factor 1 (IGF-1) and interleukin 6
(IL-6).
In the MM microenvironment, PTC-209 impaired tube formation, impaired osteoclast development and decreased
osteoblast formation in a dose-dependent manner (P < 0.01 at 1 μM, respectively). The latter might be attributed to
an induction of DKK1 and was reversed by concurrent anti-DKK1 antibody treatment.
Conclusions: We confirmed overexpression of BMI-1 in MM highlighting its role as an attractive drug target and
reveal therapeutic targeting of BMI-1 by PTC-209 as a promising novel therapeutic intervention for MM.
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Background
Multiple myeloma (MM) arises from the clonal growth
of malignant plasma cells in the bone marrow (BM) [1].
Treatment options for MM are continuously improving,
leading to significantly increased response rates as well
as prolonged survival [1, 2]. Despite this progress, mye-
loma remains a difficult-to-treat disease with the vast
majority of patients eventually relapsing. Therefore, the
identification of novel drug targets and introduction of
additional therapeutic agents are urgently needed to
improve the efficacy of existing therapies, to overcome
drug resistance and to unravel additional drugable key
players in the pathophysiology of MM.
The polycomb complex protein BMI-1 (BMI-1) consti-
tutes a pleiotropic factor with implications in the regula-
tion of the cell cycle, DNA damage response, apoptosis,
senescence as well as stem cell self-renewal and differ-
entiation [3]. BMI-1 was originally discovered as a co-
operation factor for v-myc avian myelocytomatosis viral
oncogene homolog (MYC) in lymphomagenesis and
constitutes a central component of the polycomb
repressive complex 1 (PRC1), an epigenetic repressor
complex which acts through histone H2A mono-
ubiquitination at lysine 119 [4–8]. Overexpression of
BMI-1 was frequently observed in diverse human
malignancies and associated with tumour initiation and
propagation, disease progression and poor prognosis
[9–13]. Moreover, BMI-1 was shown to mediate the
growth and survival of cancer stem cells in several solid
and haematological malignancies [14–17].
BMI-1 represents an attractive drug target in myeloma
as well. Upregulation of BMI-1 has been reported previ-
ously in MM, and silencing of BMI-1 by small hairpin
(sh) RNA significantly impaired the proliferation and
colony formation of myeloma cells [18, 19]. Further-
more, silencing of BMI-1 induced apoptosis in vitro and
in vivo through upregulation of BCL2-like 11 (Bim) ex-
pression in MM cells [19]. More recent results demon-
strated that shRNA-mediated silencing of BMI-1 also
sensitizes myeloma cells to bortezomib, which was at-
tributed to increased expression of p21 and BCL2-
associated X protein (Bax) [20]. However, despite the
identification of BMI-1 as an attractive drug target in
myeloma and various other malignancies, inhibitors spe-
cifically targeting BMI-1 have not been available so far.
Kreso et al. recently reported targeting of colorectal
carcinoma with PTC-209, a novel small molecule in-
hibitor of BMI-1 [21]. Treatment of colorectal cancer
cells reduced BMI-1 protein levels and significantly im-
paired tumour growth in vitro and in vivo. Importantly,
PTC-209 also targeted cancer-initiating cells [21].
Treatment of chronic and acute myeloid leukemia cells
with PTC-209 was likewise shown to impair tumour
growth and survival [22, 23]. We therefore aimed to
investigate the pre-clinical activity of PTC-209 in mye-
loma and to explore the impact of BMI-1 inhibition on
the tumour microenvironment.
Results
BMI-1 is overexpressed in multiple myeloma and
associated with survival
We confirmed overexpression of BMI-1 in CD138+ puri-
fied cells of monoclonal gammopathy of undetermined
significance (MGUS), smouldering multiple myeloma
(SMM), newly diagnosed and relapsed MM patients
compared to healthy controls in publically available gene
expression profiling (GEP) datasets. As expected, BMI-1
expression was significantly (P < 0.0001) elevated in MM
patients (newly diagnosed and relapsed) compared to
healthy donor bone marrow plasma cells (BMPCs). Of
note, BMI-1 expression was already increased in CD138+
cells of MGUS and SMM patients. We also examined
BMI-1 expression levels in total therapy 2 (TT2)- and
TT3-treated patients at baseline and relapse. This ana-
lysis indeed demonstrated a significant increase of BMI-
1 expression at relapse in patients treated within the
TT3 protocol (P = 0.016) (Fig. 1a). In line with this
observation, relapsed and/or refractory patients with low
BMI-1 expression treated with bortezomib or dexa-
methasone displayed a superior prognosis compared to
patients with high BMI-1 expression (median overall
survival [OS] 22.2 vs 13.7 months, P = 0.003) (Fig. 1b).
These results confirmed overexpression of BMI-1 in all
stages of MM progression and therefore highlight its pu-
tative role as an attractive drug target in myeloma.
PTC-209 impairs myeloma cell growth and survival
In line with the GEP analysis and previous reports, BMI-1
gene and protein expression was observed in eight of eight
human myeloma cell lines (HMCLs) tested (not shown).
Treatment with PTC-209 led to downregulation of BMI-1
protein levels (Fig. 2a) and significantly impaired viability
of all HMCLs analysed with IC50 values <2 μM in six of
eight HMCLs (range 0.21–5.68 μM) (Fig. 2b). No signifi-
cant association was observed between IC50 values and
BMI-1 mRNA (R =−0.32, P = 0.44) or protein expression
(R =−0.43, P = 0.29). In contrast to HMCLs, IC50 values
were not reached in healthy donor peripheral blood
mononuclear cells (PBMCs) (range 15–629 μM) and bone
marrow stromal cells (BMSCs) TERT+ cells (IC50: 54 μM)
(Fig. 2c). Analysis of gene expression after short-term in-
cubation (5 h) with PTC-209 demonstrated deregulation
of cell cycle-associated genes. We observed significant
downregulation of cyclin D1 (CCND1) (up to 0.67 ± 0.04-
fold reduction, P < 0.001) and MYC (up to 0.50 ± 0.07-fold
reduction, P < 0.001) as well as upregulation of the cell
cycle inhibitory genes cyclin-dependent kinase inhibitor
1A (CDKN1A) (up to 3.4 ± 0.4-fold increase, P < 0.001)
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and cyclin-dependent kinase inhibitor 1B (CDKN1B) (up
to 2.1 ± 0.6-fold increase, P = 0.03) (Fig. 2d). This trans-
lated into a significant accumulation of cells in the G1
phase and concurrent reduction of cells in the S and G2M
phase of the cell cycle after 24 h of treatment with PTC-
209 at 1 μM (Fig. 2e).
In addition to the anti-proliferative effects, PTC-209
significantly impaired the number and size of colonies
formed by myeloma cells in a colony formation assay
(OPM-2: 215 ± 50 vs 105 ± 12 colonies with PTC-209 at
1 μM, P = 0.005; KMS-12-BM: 59 ± 12 vs 17 ± 3, P <
0.001) and induced apoptosis in all HMCLs analysed
(Fig. 3a, b). The latter was further confirmed by the
presence of increased poly(ADP-ribose) polymerase
(PARP) cleavage and JC-1 assay, which indicated
depolarization of the mitochondrial membrane after
24 h treatment with PTC-209 (Fig. 3c, d). Of note, via-
bility 96 h post treatment with PTC-209 at 1 μM signifi-
cantly correlated with the number of apoptotic cells at
72 h post treatment (R =−0.78, P = 0.04), but not with
changes in the cell cycle profile. This suggests that
induction of apoptosis is the main mechanism respon-
sible for the reduction of viable cells upon PTC-209
treatment. We therefore assessed the regulation of mito-
chondrial genes associated with apoptosis and detected
significant induction of NOXA expression in the pres-
ence of PTC-209 (up to 3.6 ± 1.2-fold increase, P =
0.009) (Fig. 3e). In contrast, no impact of PTC-209 was
observed on Bim and Bax expression levels (data not
shown). In line with the proposed functions of NOXA,
we observed downregulation of myeloid cell leukemia 1
(MCL-1) protein levels (Fig. 3f ), suggesting that induc-
tion of apoptosis by PTC-209 is related to NOXA-
mediated inhibition of MCL-1.
PTC-209 impairs the activity of stromal support for
myeloma cells and shows synergistic activity with
pomalidomide and carfilzomib
To assess whether PTC-209 overcomes stromal-mediated
drug resistance, we tested the activity of PTC-209 in the
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Fig. 1 BMI-1 is overexpressed in multiple myeloma and associated
with outcome. a BMI-1 expression analysis of CD138+ purified cells
in publically available gene expression datasets displayed significant
overexpression in MGUS, SMM and MM patients compared to healthy
donor plasma cells. In addition, BMI-1 expression was increased at
relapse (n = 29) compared to baseline (n = 433) in patients treated
within TT3, but not in those of TT2 (n= 172 and n= 346, respectively).
Boxplots represent median BMI-1 expression (line) and 2.5–97.5 percentile
(bars). ***P< 0.001, **P< 0.01 and *P< 0.05. b High BMI-1 expression was
associated with poor outcome in relapsed and/or refractory patients
treated with bortezomib or dexamethasone (GSE9782) (n= 264).
Samples were divided into two groups based on the maximally selected
rank statistics cutoff
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interleukin 6 (IL-6). Importantly, PTC-209 was found to
impair the growth- and survival-propagating effects of
both soluble factors in a dose-dependent manner in the
non-autonomously surviving cell lines KMS-12-BM and
MM.1S. In the autonomously surviving cell line OPM-2
(proliferate in serum-free Syn-H medium), IGF-1 and IL-6
did not show any additional effect but likewise did not res-
cue OPM-2 cells from the anti-MM activity of PTC-209
(Fig. 4a). When KMS-12-BM and U266 cells were co-
cultured with human BMSCs, PTC-209 significantly in-
creased the rate of apoptotic cells (KMS-12-BM: 5.4 vs
36.1 % apoptotic cells with PTC-209 at 1 μM, P = 0.004;
U266: 8.9 vs 16.0 %, P = 0.05). Moreover, PTC-209 en-
hanced the anti-MM activity of pomalidomide and carfil-
zomib in the presence of BMSCs; although, we have to
note that there was only a marginal effect in the partial
resistant HMCL U266 (Fig. 4b). To verify the synergistic
activity of these agents, six HMCLs were incubated with
PTC-209 and either pomalidomide or carfilzomib at vary-
ing concentrations. PTC-209 displayed synergistic and/or
additive drug activity in combination with carfilzomib in
all HMCLs analysed, and in five of six HMCLs in combin-
ation with pomalidomide. Importantly, synergistic activity
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Fig. 2 PTC-209 impairs myeloma cell viability and proliferation. a PTC-209 downregulated BMI-1 protein levels in all MM cell lines analysed by
intracellular staining using flow cytometry. Histograms are representative for three independent experiments. b Reduced viability 96 h post treatment
was observed in all MM cell lines in a dose-dependent manner, but not in BMSCs or PBMCs (c). d Downregulation of CCND1 and MYC as well as
upregulation of CDNK1A and CDKN1B was noted 5 h post treatment. e Deregulation of proliferation-associated genes translated into a significant
increase of cells in the G1 phase and concurrent decrease in the S and G2M phase of the cell cycle 24 h post treatment. ***P < 0.001, **P < 0.01 and
*P < 0.05 vs DMSO control
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the PTC-209 partly resistant HMCL U266 (Fig. 4c). Simi-
lar results were obtained when PTC-209 was combined
with dexamethasone (Additional file 1: Figure S1).
PTC-209 targets the myeloma microenvironment
As PTC-209 was shown to impair stromal-mediated
drug resistance, we were interested whether it impacts
the function of other cells in the myeloma microenvir-
onment as well. Enhanced formation of osteoclasts and
angiogenesis is a major hallmark of myeloma. We there-
fore analysed the activity of PTC-209 on these cell types.
In vitro osteoclast formation of healthy donor PBMCs
was significantly impaired, with no signs of tartrate-
resistant acid phosphatase (TRAP)-positive osteoclasts
when PTC-209 was used at 1 μM (Fig. 5a). This was fur-
ther confirmed by decreased expression of cathepsin K
and TRAP (0.88 ± 0.17 and 0.78 ± 0.01-fold downregula-
tion with 1 μM PTC-209; P < 0.01, respectively) at day
14 of osteoclast formation (Fig. 5b). Similarly, PTC-209
was found to impair in vitro tube formation in a dose-
dependent manner. Treatment with PTC-209 at 1 μM
significantly decreased the total length (P = 0.005), the
branching interval (P = 0.002) as well as the number of
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Fig. 3 PTC-209 inhibits colony formation and induces apoptosis in myeloma cells. a Treatment with PTC-209 significantly inhibited colony formation
of KMS-12-BM and OPM-2 cells. Images are representative for three independent experiments. Induction of apoptosis was verified by annexin V/7-AAD
staining (b), quantification of cleaved PARP by ELISA (c) and analysis of the mitochondrial membrane potential by JC-1 assay (d) 72 and 24 h post
PTC-209 treatment, respectively. e Rapid induction (5 h) of NOXA expression was observed in all MM cell lines tested, followed by a decrease in MCL-1
protein levels 20 h post treatment analysed by intracellular staining using flow cytometry (f). Histograms are representative for three independent
experiments. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control
Bolomsky et al. Journal of Hematology & Oncology  (2016) 9:17 Page 5 of 13
respectively) of tubes formed by human umbilical vein
endothelial cells (HUVECs) after a 19-h incubation
period (Fig. 5c).
As BMI-1 is known for its close interaction with the
Wnt signalling pathway, we speculated that PTC-209
might affect osteoblast formation as well. We indeed ob-
served a significant negative impact of PTC-209 on
osteogenesis, evidenced by decreased alkaline phosphat-
ase (ALP) activity (68 ± 4 % reduction with PTC209 at
1 μM, P < 0.001) and matrix mineralization in a dose-
dependent manner (Fig. 6a). The reduction in osteoblast
formation was accompanied by a significant increase in
Dickkopf-1 (DKK1) expression at day 7 of osteogenesis
(1.5 ± 0.1-fold increase at 0.1 μM PTC-209, P < 0.001)
(Fig. 6b). We therefore investigated whether concurrent
blockade of DKK1 with a neutralizing antibody could
overcome the inhibitory effects on osteoblast formation.
Bi-weekly treatment with anti-DKK1 antibody significantly
Fig. 4 PTC-209 reduces the effect of major myeloma growth factors and stromal support as well as displays synergistic activity with pomalidomide
and carfilzomib. a PTC-209 was found to impair the growth and survival-propagating effects of IGF-1 and IL-6 in a dose-dependent manner. b The
anti-MM activity of PTC-209 was upheld in the presence of BM stromal cells and promoted the activity of pomalidomide and carfilzomib. ***P < 0.001,
**P < 0.01 and *P < 0.05 vs PBS control; ###P < 0.001, ##P < 0.01 and #P < 0.05 vs IGF-1 control; +++P < 0.001, ++P < 0.01 and +P < 0.05 vs IL-6 control. c
Additive/synergistic activity of drug combinations was confirmed by concurrent treatment of MM cell lines with PTC-209 and either pomalidomide or
carfilzomib for 96 h at varying concentrations. Graphs for MM.1S and U266 are representative for the panel of HMCLs analysed. Combination index (CI)
values were determined with CompuSyn. CI values <0.8, 0.8–1.2, or >1.2 indicate synergistic, additive or antagonistic drug activities, respectively
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increased ALP activity in the presence of PTC-209 at
1 μM (43 ± 6 vs 21 ± 12 % decrease in ALP activity, P =
0.02), suggesting that the osteoblast inhibitory proper-
ties of PTC-209 might be, at least in part, mediated by
DKK1 (Fig. 6c).
Discussion
In spite of the recent advances in the treatment of MM,
the recurrence of myeloma after response to existing
therapies is a major drawback on the way to cure. The
identification of novel therapy targets and subsequent
implementation of new anti-myeloma therapeutics is
therefore urgently needed. Based on previous reports, in-
hibition of the polycomb complex protein BMI-1 might
represent an attractive treatment approach for myeloma
[19, 20], but therapeutic agents targeting BMI-1 are not
available for clinical use so far. In the current study, we
investigated the anti-MM activity of PTC-209, a novel
small molecule inhibitor of BMI-1.
Our initial analysis of publically available GEP datasets
confirmed the overexpression of BMI-1 in MM.
Overexpression of BMI-1 has been reported in various
malignancies, including MM [18], and is typically associ-
ated with poor survival [9–13]. We likewise observed a
significant elevated expression of BMI-1 in MM as well
as in MGUS and SMM patients. Of note, BMI-1 expres-
sion was further elevated in relapsed TT3, but not TT2
patients. This suggests that the use of distinct treatment
strategies such as the addition of bortezomib in TT3
specifically impacts BMI-1 levels. According to this
assumption, shRNA-mediated silencing of BMI-1 was
shown to sensitize MM cells to bortezomib [20]. Our
observation of increased BMI-1 expression in relapsed
TT3 patients suggests that further BMI-1 upregulation
might confer a more aggressive phenotype during the
progression of MM as it was shown in the progression
of several other tumour entities [9, 12, 24–28]. This is
also evidenced by an association of high BMI-1 expres-
sion with worse overall survival in relapsed and/or
refractory patients treated with bortezomib or dexa-
methasone (Fig. 1b) [29]. These results confirmed BMI-1
overexpression in all stages of MM, from the onset of the
Fig. 5 PTC-209 impairs in vitro osteoclast and tube formation. a PTC-209 significantly inhibited osteoclast formation in a dose-dependent manner
verified by reduced numbers of multinucleated TRAP-positive cells at day 14 of differentiation. b The inhibitory impact on osteoclast formation was
confirmed by decreased expression of cathepsin K and TRAP. c Tube formation was inhibited by PTC-209 in a dose-dependent manner. Analysis with
the Angiogenesis Analyzer for ImageJ demonstrated a significant impact of PTC-209 on the total length, the number of junctions and master segments
as well as the branching interval (defined as total segments length/number of branches) during the tube formation process. Images are representative
for three independent experiments. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control
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disease until progression in response to therapy, underlin-
ing its central role as an attractive drug target in MM.
PTC-209 demonstrated significant anti-myeloma activ-
ity in all HMCLs analysed. In line with the effect of
shRNA-mediated silencing of BMI-1 [19], we observed a
significant impact on the colony formation of myeloma
cells, suggesting that targeting BMI-1 also affects the
viability of tumour-propagating cells. Recent reports
indicated that PTC-209 targets cancer-initiating cells in
colorectal and biliary tract cancer. In particular, PTC-
209 impaired sphere formation in both entities as well as
growth of aldehyde dehydrogenase-positive (ALDH+)
cells in certain biliary tract cancer cell lines [21, 30].
Future studies therefore have to clarify whether BMI-1
inhibition specifically targets tumour-propagating cells
in MM as well.
Similar to shRNA-mediated BMI-1 inhibition in breast
and lung adenocarcinoma cells [31, 32], the growth-
inhibiting effect of PTC-209 was associated with deregu-
lation of CCND1, MYC, CDKN1A and CDKN1B. These
genes are known to be implicated in the proliferation of
MM cells and their deregulation therefore likely explains
the accumulation of cells in the G1 phase and the im-
paired entry into the S and G2M phase of the cell cycle.
Induction of apoptosis was accompanied by a rapid in-
crease of NOXA expression and subsequent reduction of
MCL-1 protein levels. Prior studies reported that silen-
cing of BMI-1 in MM cells was linked to increased ex-
pression of either Bim or Bax. However, in these studies,
upregulation of Bim and Bax reached significance 48 h
post BMI-1 silencing [19, 20]. In the current study, up-
regulation of NOXA (but not Bim or Bax) was already
observed 5 h post treatment with PTC-209, suggesting
that NOXA might be upstream of Bim and Bax in the
initiation of apoptosis after impairing BMI-1. According
to this assumption, upregulation of NOXA leads to in-
creased binding of NOXA to MCL-1, thereby releasing
Bim from MCL-1 which subsequently mediates Bax (and
Bak)-dependent induction of apoptosis [33, 34]. Similar
to our results, a time-dependent increase of NOXA prior
to Bim protein levels was observed in chronic lymphatic
leukemia cells in response to histone deacetylase inhibi-
tors (HDACi). HDACi were shown to induce a rapid in-
crease of NOXA mRNA levels, which subsequently
triggers MCL-1 binding and induces apoptosis [35].
Moreover, BMI-1 was shown to mediate the survival of
memory CD4 T cells as well as mantle cell lymphoma
cells via direct binding to the NOXA gene locus and re-
pression of NOXA mRNA expression through histone
modifications [14, 36]. These findings suggest that early
upregulation of NOXA might release and activate Bim
and Bax to exert their apoptotic effects upon BMI-1
inhibition.
Importantly, the anti-MM activity of PTC-209 was up-
held in the presence of major myeloma growth factors
(IGF-1 and IL-6) as well as in co-culture with BMSCs.
Moreover, we observed synergistic activity of PTC-209
with pomalidomide, carfilzomib and dexamethasone,
suggesting that inhibition of BMI-1 might improve
Fig. 6 PTC-209 inhibits osteogenesis via upregulation of DKK1. a PTC-
209 significantly inhibited osteoblast formation in a dose-dependent
manner verified by reduced alkaline phosphatase activity and matrix
mineralization at days 14 and 21 of differentiation, respectively. Images
are representative for three independent experiments. b Treatment
with PTC-209 increased DKK1 expression in developing osteoblasts at
day 14 of osteogenesis. c The inhibitory effect of PTC-209 on osteoblast
activity was partially overcome by concurrent anti-DKK1 antibody
treatment. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO
control; #P < 0.05
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current treatment strategies. A similar observation was
made when BMI-1-silenced myeloma cells were treated
with bortezomib. Concurrent treatment enhanced the
anti-proliferative and apoptotic activity of bortezomib
via pronounced induction of p21 and Bax [20].
In addition to its direct anti-myeloma effect, we dem-
onstrated that PTC-209 showed a significant impact on
stromal compartments as well. Little is known about the
role of BMI-1 in the fate of BM environmental cells.
Low expression levels of BMI-1 were associated with
senescence in endothelial cells of the human cornea
[37]. Moreover, BMI-1 was shown to promote the angio-
genic activity of glioma and hepatocellular carcinoma
cells [38–40]. In the current study, PTC-209 significantly
inhibited osteoclast and tube formation in vitro. In-
creased osteoclast activity and formation as well as in-
duction of angiogenesis are prominent features of the
myeloma microenvironment. The interaction of mye-
loma cells and these compartments is implicated in
tumour growth, progression and drug resistance [41].
Interfering with these manifestations therefore impairs
MM cell growth and survival. Treatment with PTC-209
might thus not only target MM via direct effects on
tumour cells, but also by impairing the crosstalk be-
tween tumour and stromal cells.
BMSCs of BMI-1−/− mice were shown to undergo a
shift from osteogenesis to adipogenesis. Moreover, BMI-
1−/− mice displayed an osteopenic phenotype character-
ized by skeletal growth retardation, decreased osteoblast
numbers and activity [42, 43]. We also observed reduced
osteoblast activity and formation in the presence of
PTC-209. Considering the negative regulation of osteo-
blast development by myeloma cells, blockade of BMI-1
could aggravate these effects probably leading to
skeletal-related side effects. We therefore aimed to iden-
tify the underlying mechanism for the decreased osteo-
blast formation. As BMI-1 is known for its close
interaction with the Wnt signalling pathway [31], a
major signalling pathway in osteogenesis [44], we specu-
lated that the osteoblast inhibition observed in our study
might be related to this connection. We indeed revealed
a significant induction of DKK1 expression in developing
osteoblasts during PTC-209 treatment and that blockade
of DKK1 with a specific antibody, at least in part, re-
versed the suppressive effect of PTC-209 on osteoblast
activity. This suggests that combination therapy with
anti-DKK1 antibodies might overcome the osteoblast
suppressive effects of BMI-1 inhibition. In line with our
results, silencing of BMI-1 in breast cancer cells was
shown to impair Wnt signalling via downregulation of
Wnt ligands (e.g. Wnt3a) and upregulation of Wnt in-
hibitors including DKK1. BMI-1 knockout was shown to
upregulate DKK1 and to target cancer cells via subse-
quent downregulation of MYC and CCND1 [31].
Interestingly, short-term treatment (5 h) with PTC-209 was
found to induce DKK1 expression in myeloma cells as well
(up to 5.0 ± 1.9-fold increase, P < 0.05) (data not shown).
This assumes that targeting Wnt signalling via BMI-1
blockade might also target myeloma cells. In line with this,
inhibition of the Wnt signalling pathway was recently
shown to affect the survival of mantle cell lymphoma-
initiating cells [45]. Considering the proposed roles of Wnt
signalling in disease progression and therapy resistance
[46–48], BMI-1 inhibition could significantly improveme
existing therapies by overcoming drug resistance.
Numerous small molecule inhibitors are currently in
clinical development to improve the treatment opportun-
ities for MM patients. These include Bruton’s tyrosine kin-
ase [49], mitogen-activated protein kinase (MAPK)
signalling cascade [50], phosphoinositol-3 kinase/AKT
[51] and Bcl-2 family inhibitors [52] among others. Future
studies have to clarify which of these agents provide the
most potent anti-tumour activity, define predictive
markers for an individualized treatment approach and
examine the additive value in combination with standard
regimens. Targeting of BMI-1 represents a promising
novel therapeutic strategy among these evolving arsenals
of specific inhibitors due to its universal expression pat-
tern in MM and its impact on the myeloma microenviron-
ment. Further studies evaluating the role of BMI-1
inhibition in myeloma and the applicability of more select-
ive inhibitors (e.g. PTC596) in vitro and in vivo are there-
fore warranted.
Conclusions
We confirmed overexpression of BMI-1 in MM highlight-
ing its role as an attractive drug target. In line with this,
PTC-209 demonstrates potent anti-MM activity by target-
ing central myeloma survival genes (e.g. MYC, MCL-1),
shows synergistic activity with pomalidomide, carfilzomib
and dexamethasone, reduces the protective effect of sol-
uble factors and BMSCs in certain cell lines, and impairs
angiogenesis as well as osteoclast formation. Upregulation
of DKK1 suggests that the osteoblast suppressive effect of
PTC-209 might be overcome by concurrent antibody
treatment. Our data reveal therapeutic targeting of BMI-1
by PTC-209 as a promising novel therapeutic intervention
for MM. Further studies examining the anti-myeloma
activity of PTC-209 and more advanced BMI-1 inhibitors
(e.g. PTC596) are therefore warranted.
Methods
Reagents
PTC-209, pomalidomide and carfilzomib were obtained
from SelleckChem, dissolved in DMSO and stored
at −80 °C. Dexamethasone was obtained from Sigma-
Aldrich, dissolved in PBS and stored at −20 °C. Recom-
binant human IGF-1, IL-6, receptor activator of nuclear
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factor-kappa B ligand (RANKL) and macrophage
colony-stimulating factor (M-CSF) were obtained from
Peprotech, dissolved in PBS/BSA 0.1 % and stored at
−20 °C. Goat anti-human DKK1 neutralizing antibody
and normal goat IgG were purchased from R&D Sys-
tems, dissolved in PBS and stored at −20 °C.
Cell lines and culture conditions
Human multiple myeloma cell lines (HMCLs) U266,
KMS-12-BM, OPM-2, NCI-H929, SK-MM-1 and
RPMI8226 were obtained from the German Collection
of Microorganisms and Cell Cultures (Braunschweig,
Germany). MM.1S and MM.1R cells were kindly pro-
vided by Dr. Steven Rosen (Northwestern University,
Chicago, IL). A human bone marrow mesenchymal stro-
mal cell line immortalized by enforced expression of tel-
omerase (BMSC TERT+) was kindly provided by Dr.
Dario Campana (St. Jude Children’s Research Hospital,
Memphis, TN). All cell lines were cultivated in RPMI-
1640 medium supplemented with 10 % heat-inactivated
fetal bovine serum, 2 mM L-glutamine and 100 U/ml
penicillin/streptomycin (Gibco). BMSC TERT+ cells
were supplemented with 1 μM hydrocortisone (Sigma-
Aldrich). For co-culture experiments, 1 × 105 BMSC
TERT+ cells were seeded in 24-well plates and cultured
overnight before 2 × 105 MM cells were added per well
for 72 h.
Cytotoxicity assay
Viability was determined by using Cell Counting Kit 8
(Sigma-Aldrich) following the manufacturer’s directions.
In brief, HMCLs (2 × 104), BMSC TERT+ cells (1 × 104)
and PBMCs (2.5 × 105) were incubated in flat-bottomed
96-well plates (ThermoFisher Scientific) in the presence
of PTC-209 (0.01–10 μM) alone, or in combination with
either pomalidomide (1–5 μM) or carfilzomib (1–5 nM).
Viability assessment in the presence of recombinant
human IGF-1 (10 ng/ml) and IL-6 (10 ng/ml) was per-
formed in serum-free Syn-H medium (ABCell-Bio).
After 96 h, cells were incubated with WST-8, and ab-
sorbance was measured at 450 nm using a HTS 7000
Bio Assay Reader (Perkin Elmer).
Colony formation assay
HMCLs (2 × 103) either treated or untreated with PTC-
209 at 1 μM were plated in duplicates in 1.1 ml
methylcellulose-based medium (MethoCult Classic,
StemCell Technologies) per 6-well and incubated for
14 days (37 °C, 5 % CO2). At the end of the incubation
period, the number of colonies consisting of >40 cells
was scored using an inverted microscope with ×4, ×10
and ×20 planar objectives.
Flow cytometry
Induction of apoptosis was determined by Annexin V/7-
AAD staining (BD Biosciences). HMCLs were seeded in
the presence or absence of BMSC TERT+ cells and
treated with 0.1 % DMSO (control), PTC-209 (1 μM),
pomalidomide (1 μM) and/or carfilzomib (5 nM) for
72 h. Cells were incubated with Annexin V and 7-AAD
for 15 min in the dark before performing analysis.
Cell cycle analysis was performed after treatment of
HMCLs with PTC-209 (1 μM) for 24 h using the FxCycle™
PI/RNase Staining solution (ThermoFisher Scientific) fol-
lowing the manufacturer’s instructions.
Intracellular staining of BMI-1 and MCL-1 was per-
formed using the BD Transcription Factor Buffer Set
(BD Biosciences) according to the manual. After fixation
and permeabilization, cells were incubated with a mouse
anti-human MCL-1 antibody (ab197529, Abcam), mouse
anti-human BMI-1 antibody (562528, BD Biosciences) or
the corresponding isotype controls for 40 min at 4 °C.
Thereafter, cells were washed and analysed. All analyses
were performed on a FACScan (BD Biosciences).
Quantitative RT-PCR
Total RNA was isolated using RNeasy kit (Qiagen), and
cDNA synthesis was performed with M-MuLV reverse
transcriptase (New England Biolabs). CDKN1A, CDKN1B,
MYC, CCND1, NOXA, TRAP, cathepsin K and DKK1
expression levels were analysed by quantitative PCR
(qPCR) using TaqMan Universal PCR Master Mix and
pre-designed TaqMan gene expression assays (Applied
Biosystems). RPLPO served as endogenous control. Reac-
tions were carried out in 25 μl volumes and run on the
ABI Prism 7300 platform (Applied Biosystems). All sam-
ples were run at least in duplicates.
PARP ELISA
Levels of cleaved PARP were analysed by using a commer-
cially available ELISA kit (Invitrogen) following the man-
ual. In brief, cell lysates were incubated with cleaved PARP
detection antibody for 3 h at room temperature on an or-
bital shaker. Subsequently, wells were washed and incu-
bated with anti-rabbit IgG HRP for 30 min at room
temperature. After an additional wash step, 100 μl stabi-
lized chromogen was added per well, the plate was incu-
bated for 30 min at room temperature in the dark and
finally mixed with 100 μl stop solution per well.
Absorbance was measured at 450 nm, and levels of cleaved
PARP were determined in relation to a standard curve.
Osteogenic differentiation
BMSCs were seeded at a density of 25,000 per square
centimetre and grown to 70–80 % confluence. Osteoblast
differentiation was initiated by changing the medium to
alpha-MEM supplemented with 15 % FBS, 2 mM L-
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glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
10 nM dexamethasone, 50 μg/ml ascorbic acid and 5 mM
β-glycerophosphate (Sigma-Aldrich). Osteogenic medium
was changed every 3–4 days. PTC-209, normal goat IgG
(1 μg/ml) and/or anti-DKK1 neutralizing antibody (1 μg/
ml) were added with every medium change. Cells treated
with 0.1 % DMSO served as control. Osteoblast formation
was assessed by alkaline phosphatase activity assay and ali-
zarin red S staining as described previously [53, 54].
Osteoclast differentiation
Human PBMCs were obtained from voluntary healthy do-
nors and cultured (2.5 × 106/ml) overnight in 24-well plates
to remove non-adherent cells. Subsequently, osteoclast dif-
ferentiation was initiated by changing the medium to
alpha-MEM supplemented with 10 % FBS, 2 mM L-glu-
tamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
50 ng/ml RANKL and 25 ng/ml M-CSF in the presence or
absence of PTC-209. Medium was changed every 3–4 days.
At day 14, cultures were fixed and stained using the Acid
Phosphatase Leukocyte Kit (Sigma-Aldrich) according to
the manufacturer’s instructions. Cells were evaluated using
an inverted microscope and multinucleated TRAP-positive
cells (>3 nuclei) were scored as mature osteoclasts.
Tube formation
Tube formation was assessed following the manual of the
Angiogenesis Starter Kit (Gibco). Briefly, human umbilical
vein endothelial cells (HUVECs) were seeded in LVES-
supplemented medium 200 at a density of 2.5 × 103 cells
per square centimetre. For in vitro tube formation, 80 %
confluent cultures were harvested, and HUVECs (50,000
per 24-well plate) were plated on Geltrex® Matrix pre-
coated wells in the presence or absence of PTC-209. Tube
networks were documented 19 h post-seeding by using an
inverted microscope. Analysis was performed using the




For the illustration of BMI-1 expression in CD138+ puri-
fied bone marrow samples as well as for the assessment
of overall survival in different MM patients, following
datasets from the Gene Expression Omnibus (GEO)
were selected: GSE2658 (consisting of 559 samples from
newly diagnosed MM patients treated within the TT2
and TT3 protocol), GSE5900 (22 healthy controls, 44
MGUS patients and 12 SMM patients), GSE6477 (15
healthy controls, 22 MGUS patients, 24 SMM patients,
73 newly diagnosed and 28 relapsed MM patients),
GSE31161 (346 TT2 baseline and 127 TT2 relapse samples
as well as 433 TT3 baseline and 29 TT3 relapse samples)
and GSE9782 (264 relapsed and/or refractory MM patients
treated with bortezomib or dexamethasone). The GSE9782
dataset was established by Mulligan et al. (2007) and con-
tains data from 156 patients treated within the APEX phase
3 trial, 57 patients treated within a companion study to re-
ceive bortezomib after progressive disease with dexametha-
sone, 44 patients treated within the SUMMIT phase 2 trial
and 7 patients treated within the CREST phase 2 trial [29].
Expression and clinical data were downloaded into R
using the Bioconductor GEOquery package. For GSE6477,
GSE5900 and GSE31161, raw CEL files were downloaded
from GEO and analyses were performed on gcrma-
normalized samples in R. In case of GSE2658, correspond-
ing raw CEL files were downloaded from GEO study
GSE24080 in order to perform a gcrma-normalization on
the raw data using the ‘affy’ package from Bioconductor
(since raw CEL files are not provided in the GSE2658 data-
set). For GSE9782, mas5 expression sets were retrieved for
analysis using the GEOquery package, since raw CEL files
are not provided for this study.
Statistical analysis
Survival analysis was performed in R using the ‘survival’
package. In order to split the patients into two groups
with different survival probabilities exhibiting higher or
lower BMI-1 expression, the maximally selected rank sta-
tistics, implemented in the maxstat R package, was applied
to the BMI-1 expression data. The statistical significance
of differences in overall survival between the two groups
was calculated by the log-rank test, and survival curves
were plotted using the Kaplan-Meier method. For the ana-
lysis of in vitro experiments, two-tailed unpaired t test was
performed using Prism 5 (GraphPad Software Inc., La
Jolla, CA, USA). P values <0.05 were considered to be sta-
tistically significant. Graphs represent the mean ± standard
deviation of at least three independent experiments per-
formed in triplicates. Synergistic, additive or antagonistic
drug activities of combination treatments were deter-
mined by using CompuSyn software.
Additional file
Additional file 1: PTC-209 displays additive and synergistic activity with
dexamethasone. Additive/synergistic activity of drug combinations was
confirmed by concurrent treatment of MM cell lines with PTC-209 and
dexamethasone for 96 h at varying concentrations. Graphs for MM.1S and
U266 are representative for the panel of HMCLs analysed. Combination
index (CI) values were determined with CompuSyn. CI values <0.8, 0.8–1.2
or >1.2 indicate synergistic, additive or antagonistic drug activities,
respectively. SK-MM-1 cells did not respond to dexamethasone at the
concentrations used (viability >100 % at the end of the incubation
period); determination of CI values was thus not possible. NA not
applicable. (PDF 631 kb)
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